TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma

Chimeric antigen receptor (CAR)-T cells are effective in the treatment of hematologic malignancies but have shown limited efficacy against solid tumors. Here, we demonstrated an approach to inhibit recurrence of B cell lymphoma by co-expressing both a human anti-CD19-specific single-chain variable f...

Descripción completa

Detalles Bibliográficos
Autores principales: Noh, Kyung-Eun, Lee, Jun-Ho, Choi, So-Yeon, Jung, Nam-Chul, Nam, Ji-Hee, Oh, Ji-Soo, Song, Jie-Young, Seo, Han Geuk, Wang, Yu, Lee, Hyun Soo, Lim, Dae-Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395772/
https://www.ncbi.nlm.nih.gov/pubmed/34445415
http://dx.doi.org/10.3390/ijms22168706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395772/
https://www.ncbi.nlm.nih.gov/pubmed/34445415
http://dx.doi.org/10.3390/ijms22168706

Ejemplares similares